Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.85 |
| ▸ | GRIK1 | P39086 | 5/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | TEK | Q02763 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16008165 | 1.00 | KDR (0.85) | KDRGRIK1CA12CA1CA2 | |
| SCHEMBL16008163 | 1.00 | KDR (0.85) | KDRGRIK1CA12CA1CA2 | |
| SCHEMBL16008186 | 0.92 | KDR (1.00) | KDRCA12CA1CA2CA9 | |
| SCHEMBL16008183 | 0.92 | KDR (1.00) | KDRCA12CA1CA2CA9 | |
| SCHEMBL16008185 | 0.92 | KDR (1.00) | KDRCA12CA1CA2CA9 | |
| SCHEMBL16008046 | 0.84 | KDR (1.00) | KDRCA12CA1CA2CA9 | |
| SCHEMBL16008043 | 0.84 | KDR (1.00) | KDRCA12CA1CA2CA9 | |
| SCHEMBL2264236 | 0.81 | KDR (0.58) | KDRGRIK1CA12CA1CA2 | |
| SCHEMBL5271094 | 0.81 | KDR (0.69) | KDRGRIK1CA12CA1CA2 | |
| SCHEMBL16008305 | 0.80 | KDR (1.00) | KDRCA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321721-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2016-04-26 | — | — | US | claimed |
| WO-2014138452-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2014-09-12 | — | — | WO | claimed |
| US-20140256819-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | claimed |
| US-9321721-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| WO-2014138452-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2014-09-12 | — | — | WO | disclosed |
| US-20140256819-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256819-A1 | KINASE INHIBITORS | CDK1, MAP3K1, MAPK1 | KDR 322/4885GRIK1 707/4885CA12 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.